New York – February 25, 2026 – Cooley advised Vivtex, a biotechnology company transforming the oral delivery of therapeutics, on its partnership with Novo Nordisk, a leading global healthcare company, to develop next-generation oral biologic medicines for obesity, diabetes and associated comorbidities. Under the agreement, Vivtex will license select oral drug-delivery technologies to Novo Nordisk and is eligible to receive upfront consideration, research funding and milestone payments totaling up to $2.1 billion, as well as tiered royalties on future product sales.

The collaboration aims to enable the oral delivery of biologic drug candidates that are traditionally limited to injectable administration due to poor absorption in the gastrointestinal tract. The partnership combines Novo Nordisk’s deep expertise in peptide and protein therapeutics with Vivtex’s proprietary gastrointestinal screening and formulation platform to identify next-generation oral therapeutics. Following research and formulation selection, Novo Nordisk will assume responsibility for global development, regulatory activities, manufacturing and commercialization of any resulting products.

A cross-office life sciences partnering team of Christophe Beauduin and Jameson Davis led the Cooley team advising Vivtex, with invaluable support from Ritu Gupta.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation.

Cooley has nearly 1,400 lawyers across 19 offices in the United States, Asia and Europe, and a total workforce of more than 3,000 people.

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as "Cooley"). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction, and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. When advising companies, our attorney-client relationship is with the company, not with any individual. This content may have been generated with the assistance of artificial intelligence (Al) in accordance with our Al Principles, may be considered Attorney Advertising and is subject to our legal notices.